Direct-acting antivirals for RSV treatment, a review

Bonneux, Brecht; Jacoby, Edgar; Ceconi, Martina; Stobbelaar, Kim; Delputte, Peter; Herschke, Florence

doi:10.1016/j.antiviral.2024.105948

Cited by 4 publications

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Vaccine and therapeutic agents against the respiratory syncytial virus: resolved and unresolved issue

Li,

et al. 2024

MedComm

View full text Add to dashboard Cite

Respiratory syncytial virus (RSV) is a predominant pathogen responsible for respiratory tract infections among infants, the elderly, and immunocompromised individuals. In recent years, significant progress has been made in innovative vaccines and therapeutic agents targeting RSV. Nevertheless, numerous challenges and bottlenecks persist in the prevention and treatment of RSV infections. This review will provide an overview of the resolved and unresolved issues surrounding the development of vaccines and therapeutic agents against RSV. As of September 2024, three RSV vaccines against acute lower respiratory infections (ALRI) have been approved globally. Additionally, there have been notable progress in the realm of passive immunoprophylactic antibodies, with the monoclonal antibody nirsevimab receiving regulatory approval for the prevention of RSV infections in infants. Furthermore, a variety of RSV therapeutic agents are currently under clinical investigation, with the potential to yield breakthrough advancements in the foreseeable future. This review delineates the advancements and challenges faced in vaccines and therapeutic agents targeting RSV. It aims to provide insights that will guide the development of effective preventive and control measures for RSV.

show abstract

Vaccine and therapeutic agents against the respiratory syncytial virus: resolved and unresolved issue

Li,

et al. 2024

MedComm

View full text Add to dashboard Cite

show abstract

Hypothetical molecular mechanism of a novel class of bacteriocin-based antivirals for the inhibition of respiratory Syncytial Virus (RSV)

Molina,

Yamasqui Padilla,

Aguaiza Pichazaca

et al. 2025

Medical Hypotheses

View full text Add to dashboard Cite

Efficacy and safety of an mRNA-based RSV preF vaccine in preclinical studies

Bai,

Li,

Gao

et al. 2024

Preprint

View full text Add to dashboard Cite

The transmembrane fusion (F) protein of RSV plays important roles in RSV pathogenesis as it mediates the fusion between virus and the target cell membrane. During the fusion process, F protein transits from a metastable state (prefusion, preF) to a stable state after merging of virus and cell membranes (postfusion, postF). The majority of highly neutralizing antibodies induced by natural infection or immunization targets the preF form, making it the preferred antigen for vaccine development. Here, we evaluate the mRNA vaccine candidate, STR-V003, which encapsulates the modified mRNA encoding the preF protein in lipid nanoparticles (LNPs). This vaccine demonstrated robust immunogenic in both mice and cotton rats. STR-V003 induced high levels of neutralizing antibodies and RSV preF-specific IgG antibodies, and significantly reduced the RSV viral loads in the lung and nose tissue of challenged animals. In addition, STR-V003 did not have obvious enhancement of lung pathology without causing vaccine enhanced disease (VED). The repeated dose general toxicology studies and local tolerance studies of STR-V003 were evaluated in rats. Therefore, STR-V003 has an acceptable safety profile and robust protective immunity against RSV, and has been approved by the FDA to enter phase I clinical study (NCT06344975).

show abstract

Direct-acting antivirals for RSV treatment, a review

Cited by 4 publications

References 59 publications

Vaccine and therapeutic agents against the respiratory syncytial virus: resolved and unresolved issue

Vaccine and therapeutic agents against the respiratory syncytial virus: resolved and unresolved issue

Hypothetical molecular mechanism of a novel class of bacteriocin-based antivirals for the inhibition of respiratory Syncytial Virus (RSV)

Efficacy and safety of an mRNA-based RSV preF vaccine in preclinical studies

Contact Info

Product

Resources

About